Sanofi, a French multinational pharmaceutical company, completed the acquisition of Kymab, a clinical-stage biopharmaceutical company developing fully human monoclonal antibodies with a focus on immune-mediated diseases and immuno-oncology therapeutics, from Malin, a company investing in highly innovative life sciences companies, and Schroder UK Public Private Trust, a closed-ended investment company, for $1.1bn. As part of the deal value, Kymab can receive up to $350m upon achievement of certain milestones. “The Kymab acquisition adds KY1005 to our dynamic pipeline, a potential first-in-class treatment for a range of immune and inflammatory diseases. The novel mechanism of action may provide treatment for patients with suboptimal responses to available therapies. We understand from our ongoing work in debilitating immunological diseases how critical it is to find the right treatment for each patient. We look forward to rapidly developing this investigational medicine," Paul Hudson, Sanofi Chief Executive Officer.